Bridging the Health Gaps in Hereditary Angioedema: Demystifying Disparities, Enhancing Quality of Life, and Implementing Effective Prophylactic Solutions
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Overview
Provider Statement
Jointly provided by Partners for Advancing Clinical Education (PACE) and CMEology
Support Statement
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Target Audience
This activity is intended for allergists, immunologists, primary care physicians, advanced care providers, and other health care providers (HCPs) involved in the management of patients with hereditary angioedema (HAE).
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify factors that contribute to health disparities in patients with Hereditary Angioedema (HAE)
- Integrate methods into clinical practice to assess how quality of life is impacted beyond acute attacks of HAE
- Implement a long-term prophylaxis plan for prevention or reduction of HAE attacks
Statement of Need
Hereditary angioedema (HAE) is a rare, life-threatening disorder characterized by recurrent, unpredictable episodes of bradykinin-induced swelling. In this presentation, Dr. Marc Riedl, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center, reviews multiple underrecognized factors that contribute to health disparities among patients with HAE, including delays in diagnosis and multifaceted differences among racial and ethnic groups, socioeconomic status levels, and access to care. The ability to recognize and strategize ways to address these disparities is crucial for optimal HAE management. Likewise, employing an effective long-term prophylactic treatment plan according to current guidelines can improve outcomes for patients with HAE. Finally, recent guidelines are reviewed in the course, emphasizing the importance of addressing HAE quality-of-life measures.
Faculty
Marc Riedl, MD, MS
Professor of Medicine
HAE Community Endowed Chair
Clinical Director – US HAEA Angioedema Center
Clinical Service Chief – Division of Allergy & Immunology
University of California, San Diego
San Diego, California
Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occured within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Marc Riedl, MD, MS
Researcher for BioCryst, BioMarin, CSL Behring, Ionis, KalVista, Pharvaris, Takeda
Consultant, Advisor, Speaker for Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Pfizer, Pharming Group, Pharvaris, Sanofi-Regeneron, Takeda
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and CMEology. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
How to Participate in this Activity and Obtain CME Credit
There are no fees for participating in and receiving credit for this activity. During the period TBD through TBD, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form. Participants must also score at least 70% on the postassessment.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.